Breast Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Women aged 18 to 50 years old.
- Women who had not yet gone through menopause at the time their breast cancer was diagnosed (based on self-reporting).
- People diagnosed with breast cancer (in one or both breasts) who were treated at the Institut Bergonié with chemotherapy (with or without targeted therapy or immunotherapy) and surgery (with or without breast removal), and/or hormone therapy, and/or radiotherapy.
- People who finished their cancer treatment at least 6 months ago — including any Herceptin treatment — with the exception of ongoing hormone therapy, which is still allowed.
- People whose breast cancer is currently in complete remission (no signs of cancer remaining).
- People who do not have a weakened immune system.
- People who are willing to sign and date a written consent form before any study procedures begin.
- People who are affiliated with the French social security system, in line with French public health law (confirm with trial site).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People with a history of, or currently living with, an autoimmune disease, immune system deficiency, or who are taking medication that suppresses the immune system — a 6-month period off such treatment is required before joining.
- People who are currently having, or planning to have, skin peeling, laser, ultrasound, botox, or hyaluronic acid treatments during the study, or who have had any of these treatments in the 6 months before the study.
- People who have skin conditions, inflammation, or infections (such as acne, cold sores, or scars) at or near the area where treatment would be applied.
- People with a known allergy or sensitivity to lidocaine, other similar local anaesthetics, hyaluronic acid, or proteins from gram-positive bacteria, or who have a history of severe allergic reactions or anaphylactic shock.
- People with a history of streptococcal disease, such as recurring throat infections or rheumatic fever.
- People with autoimmune or heart conditions (such as heart rhythm or conduction problems), or who are taking medication for heart disease such as beta-blockers.
- People with liver insufficiency or who are receiving treatment for liver disease.
- People with epilepsy that is not controlled by treatment, or who have porphyria.
- People who tend to develop raised or thickened scars (hypertrophic scarring).
- People with a serious, ongoing, or uncontrolled health condition that could put them at risk during the study or affect the study results.
- People who are taking or planning to take high-dose Vitamin E, aspirin, anti-inflammatory medications, or blood thinners in the week before each injection.
- People receiving any long-term medication or any treatment that, in the opinion of the treating doctor running the trial, could interfere with results or pose an undue health risk.
- People who are under legal guardianship or equivalent legal protection.
- People who are pregnant or currently breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Facial appearance following facial hyaluronic acid injection following breast cancer treatment.; Health-related quality of life followig facial hyaluronic acid injection following breast cancer treatment.; Adverse effects following facial hyaluronic acid injection following breast cancer treatment.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.